BioSpace News Archive

Globus Medical, Inc., a leading musculoskeletal solutions company, announced its financial results for the quarter ended June 30, 2023.

DURECT Corporation announced that the company will report its financial results for the three months ended June 30, 2023 on Wednesday, August 9, 2023.

Merrimack Pharmaceuticals, Inc. announced its second quarter 2023 financial results for the period ended June 30, 2023.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided business updates and preliminary financial results for the six-month period ending June 30, 2023.

The global glaucoma market size was estimated at USD 8.06 billion in 2022 and it is projected to hit around USD 12.69 billion by 2032, growing at a CAGR of 4.64% from 2023 to 2032. The glaucoma market in the United States was accounted for USD 3 million in 2022.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis and obesity, announced that it has granted as of August 1, 2023 an equity inducement award to one new employee under the terms of the 2022 Employment Inducement Award Plan.

Piramal Pharma Limited, announced its consolidated results for the first quarter ended 30th June 2023.

Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming UBS MedTech, Tools and Genomics Summit.

Cue Health announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to develop a Flu A/B, RSV, and COVID-19 molecular multiplex test for both over-the-counter and point-of-care use.